Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
JAKis were associated with an elevated risk of malignancy but no significant difference in the risk of 3P-MACE and serious infection among all patients with RA. Further data are needed regarding the risk of malignancy and 3P-MACE in patients with UC.
Authors
- Ju Hwan Kim (ORCID: https://orcid.org/0000-0001-7253-6515)
- Ju‐Young Shin (ORCID: https://orcid.org/0000-0003-1010-7525)
- Dongwon Yoon (ORCID: https://orcid.org/0000-0002-9369-0789)
- Farzin Khosrow‐Khavar (ORCID: https://orcid.org/0000-0003-3636-8918)
- Yongtai Cho (ORCID: https://orcid.org/0000-0003-3303-7881)
- Minkyo Song (ORCID: https://orcid.org/0000-0002-9412-2871)
- Eun Ha Kang (ORCID: https://orcid.org/0000-0001-9697-1159)
Institutions
- Rutgers, The State University of New Jersey (US)
- National Institutes of Health (US)
- Samsung (South Korea) (KR)
- Seoul National University Bundang Hospital (KR)
- National Institute on Aging (US)
- Rutgers Cancer Institute (US)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Internal Medicine
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1111/joim.20064
- Citations
- 5
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 8.34
Funders
- Ministry of Food and Drug Safety